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Introduction
For decades health expenditures have increased exponentially in most industrialized countries.
In the US, health spending increased a staggering 787 percent between 1980 and 2007. In reunified Germany, health expenditures increased from 1992 to 2008 by 60 percent, consuming more than 10 percent of GDP in 2010 (German Federal Statistical Office, 2010) . In light of these figures, it is no surprise that rising health care costs are one of the most contentious issues and a matter of great concern for policy makers worldwide.
Researchers have identified various key factors behind rising health expenditures, including demographic change, increasing national incomes, and technological change. Newhouse (1992) and Weisbrod (1991) are among the first to identify technological change as the dominant driving force, a conjecture that is difficult to empirically prove (Weisbrod, 1991; Newhouse, 1992; Okunade, 2004; Di Matteo, 2005; Civan and Koksal, 2010) .
While the main causes of rising health expenditures seem clear, the question of how to deal with them remains unresolved. There is an extremely wide variety of organizing health care systems in different countries, but none of them have emerged with an optimal model. This comes as no surprise if one thinks about the very different objectives that the different health care systems are designed to achieve: reducing the burden on the social security system and taxpayers, achieving equal access to care, providing universal coverage, avoiding state rationing, allowing freedom to choose medical providers and insurance plans, or promoting medical progress, to name just a few.
The literature analyzes the optimal organization of health care theoretically as well as empirically, although the majority of work is theoretical in nature. Some attention is given to the supply side, particularly to the question of how to optimally organize and finance a hospital system with the aim of balancing quality of care against costs (Ellis and McGuire, 1996; Sloan et al., 2001; Propper et al., 2004; Bazzoli et al., 2008) . Analogously, the same question can be raised for the outpatient sector and physicians (Mariñoso and Jelovac, 2003; Dusheiko et al., 2006; Karlsson, 2007) . Especially in the US-a market still dominated by private health care providers-there is considerable debate surrounding the question of whether Health Maintenance Organizations (HMOs) can help reduce health expenditures while maintaining quality (Goldman et al., 1995; Hill and Wolfe, 1997; Keeler et al., 1998; Deb and Trivedi, 2009 ). In Europe, on the other hand, key concerns revolve around issues of direct rationing (by public authorities) and indirect rationing (through waiting times) (Propper et al., 2002; Schut and de Ven, 2005; Felder, 2008; Siciliani et al., 2009 ).
In the demand-side research, cost-sharing is identified as the main tool used to reduce moral hazard and overconsumption of medical services (Pauly and Blavin, 2008; van Kleef et al., 2009) . In this strand of the literature, the RAND Health Insurance Experiment (HIE) is still the largest and most influential health policy study to this day. In this 1970s era study, families at six different sites in the US were randomly assigned to 14 different health insurance plans with a varying degree of cost-sharing and observed for periods up to five years (Manning et al., 1987) . Since then, a great amount of publications on the impact of cost-sharing on the demand for medical care emerged from the HIE, most published in the 1980s (see Zweifel and Manning (2000) for an overview). But apart from the HIE, there is only scant empirical evidence of causal effects of cost-containment measures on the demand for health care. A handful of studies empirically investigate how increased copayments affect the demand for doctor visits (Chiappori et al., 1998; Voorde et al., 2001; Cockx and Brasseur, 2003; Winkelmann, 2004; Gerfin and Schellhorn, 2006) . Schreyögg and Grabka (2010) analyze the effects of the copayments for doctor visits introduced in Germany. Using a difference-in-differences setup, similar to the one in this study, as well as the same dataset, they do not find any significant behavioral reactions in the aftermath of the reform.
To the best of my knowledge, this is the first paper evaluating the effectiveness of four different cost containment measures within an integrated framework. In Germany, beginning in 1997, various health reforms were implemented to reduce the demand for convalescent care.
Before the reforms went into effect, experts claimed that around a quarter of all convalescent care therapies were unnecessary (Schmitz, 1996; Sauga, 1996) . In 1995, 1.9 million patients in Germany underwent convalescent care therapy and more than e 7 billion (0.4 percent of GDP) was spent on these programs (German Federal Statistical Office, 2010) . Ziebarth (2010) shows that the price elasticity of demand for convalescent care treatments is inelastic and about -0.4-an estimate that is very much in line with the consensus price elasticity estimates in the literature on health care (Wedig, 1988; Keeler et al., 1988; Zweifel and Manning, 2000) . Hence, it is plausible to assume that convalescent care is a good proxy for health care in general.
The first reform evaluated here doubled the daily copayments for convalescent care. The second increased waiting times between two treatments and reduced the legally codified standard length of the therapy. The third reform gave employers the right to deduct two days of paid vacation for every five days that employees were unable to work while in convalescent care. The fourth reform cut statutory sick pay from 100 to 80 percent of foregone gross wages during convalescent care.
The first two reforms only affected people insured under the German Mandatory Health Insurance (MHI), while people insured under the second tier of the German health insurance system-the Private Health Insurance (PHI)-were not affected. The other two reforms, which concerned the cut in paid leave, only affected private-sector employees. Thus, I can define various subgroups that were affected differently by the reforms. By means of conventional differencein-differences models and SOEP panel data, I then disentangle the causal effects of these cost containment measures on the demand for convalescent care. One main objectives of this paper is to evaluate the effectiveness of direct cost containment measures such as copayment increases, which apply to the entire population, as compared to indirect measures such as decreasing legal minimum requirements, which only increase employers' options to regulate work conditions at the firm level.
My empirical results show that doubling the copayments was, by far, the most effective cost containment instrument. It led to a significant decrease in the demand for convalescent care programs of about 20 percent. Moreover, evidence from administrative data suggests that the reduction in the legally defined standard length of the therapies was effective in reducing the average duration of treatments. However, I do not find evidence that the cuts in paid leave significantly reduced the demand for convalescent care programs.
Based on administrative data, back-of-the-envelope calculations suggest that all reforms jointly reduced annual public spending for convalescent care by e 800 million or 13 percent.
Although the length of treatments decreased, the doubling of daily copayments raised additional revenues of about e 400 million per year.
In the next section, I describe some features of the German health care system and give more details about the reform. In Section 3, the dataset and the variables used are explained, and in the subsequent section, I specify my estimation and identification strategy. Estimation results are presented in Section 5 and I conclude with Section 6.
The German Health Care System and the Policy Reforms
The German health care system is actually comprised of two independent health care systems that exist side by side. The more important of the two is the Mandatory Health Insurance (MHI), which covers about 90 percent of the German population. Employees whose gross income from salary is below a defined income threshold (in 2010, e 49,950 per year) are compulsorily insured under the MHI. High-income earners who exceed that threshold as well as self-employed people have the right to choose between the MHI and private health insurance. Non-working spouses and dependent children are covered at no cost by the MHI family insurance. Special regulations apply to particular groups such as students and the unemployed, but most of these are MHIinsured. Everyone insured under the MHI is subject to a generous universal benefit package, which is determined at the federal level and codified in the Social Code Book V (SGB V).
Coinsurance rates 1 are prohibited in the MHI and thus, apart from copayments, health services are fully covered. The MHI is one pillar of the German social security system (German Ministry of Health, 2010).
The MHI is primarily financed by mandatory payroll deductions that are not risk-related.
For people with gainful employment, these contributions are split equally between employer and employee up to a contribution ceiling (2010: e 45,000 per year). Despite several health care reforms that tried to remedy the problem of rising health care expenditures, contribution rates have risen from 12.6 percent in 1990 to 15.5 percent in 2011, mainly due to demographic changes, medical progress, and system inefficiencies (German Federal Statistical Office, 2010) .
The second track of the German health care system is Private Health Insurance (PHI). The main groups of private insurance holders are private-sector employees above the aforementioned income threshold, public-sector employees 2 , and the self-employed. Privately insured people pay risk-related insurance premiums determined by an initial health checkup. The premiums exceed the expected expenditures in younger age brackets, since health insurance providers build up reserves for each insured person for rising expenditures with increased age. Coverage is provided under a range of different health plans, and insurance contracts are subject to private law. Consequently, in Germany, public health care reforms apply only to the MHI, not to the PHI.
1 Coinsurance rates are important for private health insurance providers. They differ from copayments. While a copayment is typically a fixed amount that the insured person has to pay per day of treatment or for specific medical devices or medications, a coinsurance rate defines a percentage of the costs that an insured person has to pay when using the system. For example, private health insurance providers may offer 80/20 health plans in which the insured person pays 20 percent of all costs incurred while the health insurance provider pays the remaining 80 percent. Often, health insurance providers limit the total amount that an individual has to spend out-of-pocket with a so-called coinsurance cap, which might be e 2,000 per year.
2 We need to distinguish between two types of employees in the German public sector: first, civil servants with tenure (Beamte), henceforth called "civil servants," most of whom purchase PHI to cover the 50 percent of health expenditures that the state does not reimburse (Beihilfe), and second, employees in the public sector without legal tenure (Angestellte imöffentlichen Dienst), henceforth called "public servants," who receive some additional benefits but are mainly insured under the MHI (under the same conditions as everyone else).
It is important to keep in mind that compulsorily insured persons have no right to choose the health insurance system or benefit package. They are compulsorily insured under the standard MHI insurance scheme. Once an optionally insured person (a high-income earner, self-employed person, or civil servant) opts out of the MHI system, it is practically impossible to switch back.
Employees above the income threshold are legally prohibited from doing so, while those who fall below the income threshold in subsequent years may do so under certain conditions, but any reserves that they have built up under PHI policies are not transferable (neither between PHI and MHI, nor between different private health insurance providers). 3 In reality, switching to a private health insurance provider may be regarded as a lifetime decision, and switching between the MHI system and PHI-as well as between PHI providers-is therefore very rare.
The German Market for Convalescent Care
In Europe, especially in Germany, there is a long tradition of health spa treatments to improve poor health. Since the time of the Roman Empire, doctors have sent patients to "take the waters" to recover from various disorders. In Germany, convalescent care treatments are usually combined with various types of physical therapy, often including electrotherapy, massage, underwater exercise, ultrasonic therapy, health and diet education, stress reduction therapy, and cold and hot baths as well as mud packs. Convalescent care therapies require the patients to follow a strict daily schedule.
The German MHI is one of the few health insurance systems worldwide that, apart from small copayments, fully covers convalescent care therapies at health spas. It may therefore come as no surprise that the German market for convalescent care is said to be the largest worldwide.
In 1995, a total of e 7.646 billion was spent on convalescent care, accounting for more than 4 percent of all health expenditures in Germany. Around 1,400 medical facilities with 100,000 full-time (equivalent) staff members treated 1.9 million patients, who stayed an average of 31 days each (German Federal Statistical Office, 2010) . 
The Cost Containment Policy Reforms
At the end of 1996, the German government implemented four health care reforms. The first three were designed to dampen the demand for convalescent care programs directly, based on the suspicion of a high degree of moral hazard in the market for convalescent care. Prior to the reform, experts estimated that around a quarter of all treatments prescribed were unnecessary (Schmitz, 1996; Sauga, 1996) . The fourth reform was designed to tackle moral hazard in the decision to take sick leave and may have indirectly affected the demand for convalescent care as well.
The first reform doubled daily copayments. In West Germany, as of January 1, 1997, copayments for convalescent care therapies increased from DM 12 (e 6.14) per day to DM 25 (e 12.78) per day. In East Germany, the copayments increased from DM 8 (e 4.09) to DM 20 (e 10.23) per day. This reflects an increase of 108 (150) percent. 4 To illustrate how drastic this copayment increase really was, I multiply the daily copayment rates by the average length of stay according to the Federal Statistical Office (German Federal Statistical Office, 2010) . The absolute increase per treatment amounted to around e 150 in East and West Germany. Before the reform and in relation to the monthly net wages of those who received convalescent care in my sample, the total copayment per treatment was 12 percent of the monthly net wage in East Germany and 13 percent in West Germany. After the copayment increase, the total copayment sum per treatment approximately doubled to 25 (East) and 24 (West) percent of the average monthly net wage.
The second reform reduced the standard length of convalescent care therapies from four to three weeks. Only the medical personnel of the facility-after consultation with the sickness fund-have the authority to approve deviations from the standard, legally codified, length of therapy. Together with this reduction in therapy duration, waiting times were increased from three to four years between treatments. Both reform elements-the reduced standard length of therapy and the extended waiting period-are only effective conditional on the non-existence of urgent medical reasons for treatment.
The third reform allowed employers to deduct two days of paid vacation for every five days that an employee was unable to work due to convalescent care therapy. The fourth reform decreased statutory short-term sick pay from 100 to 80 percent of foregone gross wages. German social legislation provides employees with paid leave for convalescent care treatments in addition to paid vacation. Hence, one would expect that the latter two reforms, which allowed employers more leeway in reducing paid leave, to have an effect on the demand for convalescent care. 5
[Insert Table 1 about here] Table 1 displays the various subgroups of insured people who were affected differently by the four cost containment measures. Subgroup (1) comprises the vast majority of Germans: privatesector employees who are insured under the MHI. They were affected by all reforms discussed above. I define them as Treatment Group 1.
In contrast, subgroups (2) to (5) were not affected by either the cut in statutory sick pay or the cut in paid vacation. Non-working and self-employed people are not eligible for paid leave.
Public-sector employees and apprentices were exempted from the cuts in paid leave. However, since they were insured under the MHI, they were affected by the first two reforms. I call these subgroups jointly Treatment Group 2.
Subgroups (6) to (9) were completely unaffected by all legislative changes; they also consist of the non-working, the self-employed, apprentices, and public sector employees, none of whom were affected by the cut in paid leave. However, in contrast to Treatment Group 2, subgroups (6) to (9) were insured under the PHI and, thus, reforms one and two did not apply to them either. I define subgroups (6) to (9) jointly as Control Group. 6 In total, I obtain three mutually exclusive subsamples that were affected differently by the reforms. Thus, in the empirical assessment, I use three distinct main models in which I compare these subsamples to evaluate the effectiveness of the reforms. To this end, I generate three treatment indicators that I will explain in more detail in Section 3.3 below.
Dataset and Variable Definitions 3.1 Dataset
The empirical analysis relies on micro data from the German Socio-Economic Panel Study (SOEP). The SOEP is an annual representative household survey that started in 1984 and meanwhile includes more than 20,000 respondents. Wagner et al. (2007) provide further details.
Information on convalescent care treatments is only available for two post-reform years. Hence, for the core analyses, I use data from the 1995 to 1999 waves, which include time-invariant information, current information, and retrospective information about the previous year. Since the dependent variable contains information about the calendar year prior to the interview, I employ data on the years 1994 to 1998. 7 I exclude respondents under the age of 18, who are exempted from copayments, and focus on the subgroups defined in Table 1 .
Dependent Variable and Covariates
The SOEP contains various questions about health insurance and the use of health care services.
The dependent variable convalescent care measures whether a respondent received convalescent care at a health spa in the calendar year prior to the interview; it takes the value one if that was the case, and zero if not. In other words, convalescent care measures the overall incidence of convalescent care programs. The variable has been generated from the following question, which was asked in every wave from 1995 to 1999: "Did you go to a health spa for convalescent care in 199X?" In German, this question is even clearer because of the well-known umbrella term Kur and the inpatient treatment this entails, at a location other than the recipient's place affected by reforms three and four but not by the increase in copayments or in waiting times. However, in my sample, they consist of only 150 respondents per year and, thus, I cannot use them to obtain precise estimates.
7 If the respondent was interviewed in two subsequent waves, e.g., in 1994 and 1995, I match time-variant data from questions posed in the first year dealing with the first year with retrospective data obtained from questions posed in the second year dealing with the first year. For example, in 1995, respondents were asked about their current health status and about their insurance status during the previous year. Hence, I use the 1994 data on health status together with the 1995 data on insurance status if the respondent was interviewed in both years.
of residence, a Kurort or spa town, which minimizes measurement errors. The fact that we do not know the exact period of the therapy does not severely hamper the analysis, especially since such treatments are usually not carried out over Christmas or New Year's. Hence, there should be no doubt as to whether the therapy was in 1996 or in 1997.
While convalescent care can be considered a fairly good measure of the incidence of convalescent care treatments, the SOEP does not include a measure of their duration. However, as explained above, the length of treatment is regulated by social law and deviations from it are solely determined by the medical personnel and the MHI sickness fund, not by the patient.
Therefore, the empirical analysis focuses mainly on the effects on the incidence, which is the key behavioral parameter in this setting and mainly influenced by the patient. I use aggregated administrative data on the average duration of treatments as an additional outcome measure in descriptive assessments later on.
In my main empirical models, I make use of various control variables. These control variables capture personal and family-related characteristics such as age, female, immigrant, partner, and children. Moreover, I control for educational characteristics by using data on the highest educational degree obtained. An important determinant of the demand for convalescent care programs is the health status of the respondents, which I observe and control for (in form of self-assessed health). I also include covariates that measure whether the person was employed full-time, part-time, marginally, or not at all. 8 I additionally control for gross monthly income.
To capture time-invariant regional characteristics, I make use of 15 state dummies. Regional labor market dynamics are controlled for by the inclusion of the annual state unemployment rate. Time trends are captured by year dummies. A list of the covariates, as well as its means and standard deviations are found in Appendix A.
Treatment Indicators
In Section 2.2, I define three mutually exclusive subsamples that were affected by different reform elements, as shown in Table 1 . In the next section, I make use of three distinct models to assess the effectiveness of the various reforms. This requires three distinct treatment indicators for the three models to compare the different subsamples.
T1 has a one for employees in Treatment Group 1 and a zero for respondents in the Control 8 Non-employment in particular may change quickly. Hence, the assignment of respondents to the treatment and control group might be imprecise. Since the MHI/PHI status is very stable over time, the imprecision lies between the different subgroups that were insured under the MHI as well as between the different subgroups that were insured under the PHI.
Group. By using this treatment indicator in Model 1, I compare those who were affected by all reforms with those who were completely unaffected to assess the net effect of all reforms jointly on the demand for convalescent care programs.
T2 has a one for employees in Treatment Group 2 and a zero for respondents in the Control Group. Thus, in Model 2, I contrast those who were affected by the first two reforms with the non-treated. In this model, my main intention is to evaluate the effectiveness of the copayment doubling, i.e., the first reform. In extended robustness checks, I will also assess the effect of the second reform by means of Model 2.
T3 is used in Model 3, which assesses the effectiveness of the cuts in paid leave. For this purpose I compare Treatment Group 1 with Treatment Group 2. Thereby I extract the effect of the first two reforms from the net reform effect to obtain the effect of the cuts in paid leave.
Estimation Strategy 4.1 Difference-in-Differences
I would like to measure how each reform affected the incidence of convalescent care programs.
Thinking of the policy intervention as a treatment, I fit probit models of the form:
where y it stands for the incidence of convalescent care programs, convalescent care. post97 t is a dummy that takes on the value one for post-reform years and zero for pre-reform years.
Depending on the model, T it stands for one the three treatment indicators (see Section 3.3 above). The interaction term between the two dummies gives us the difference-in-differences (DiD) estimator. To evaluate how the reform affected the outcome variable y it , henceforth, I
always compute and display the marginal effect of the interaction term ∆Φ(.) ∆(post97×T ) . 9 Φ(.) is the cumulative distribution function for the standard normal distribution. By including additional time dummies, ρ t , I control for common time shocks. State dummies, φ s , account for permanent differences across the 16 German states along with the annual state unemployment rate that 9 Puhani (2008) shows that the advice of Ai and Norton (2004) to compute the discrete double difference
is not relevant in nonlinear models when the interest lies in the estimation of a treatment effect in a difference-in-differences model. Using treatment indicators, the average treatment effect on the treated is given by
which is exactly what is calculated and presented throughout the paper. controls for changes in the tightness of the regional labor market and that is included in the K × 1 column vector s it . The other K − 1 regressors are made up of personal controls including health status, educational controls, and job-related controls as explained in Section 3.1.
Identification
The identification strategy relies on DiD estimation and hence on the assumption of a common time trend of the outcome variable for treatment and control group in the absence of the policy intervention. This assumption should hold conditional on all available covariates. In almost all natural experiments and non-randomized settings, controlling for a rich set of covariates is important since the control and treatment groups differ with respect to most of the observed characteristics. This is also true in the present case, as Table 2 shows. For example, in comparison to the Control Group, Treatment Group 1 includes more females and immigrants, and the employees are less educated. As compared to the Control Group, the people in Treatment Group 2 are younger and more likely to be full-time employed.
[Insert Table 2 about here]
As can be seen in Table 3 , the most important driver of the demand for convalescent care programs is health status. Not surprisingly, age also plays a role, as well as income. Immigrants are less likely to receive convalescent care, probably because of information asymmetries.
[Insert Table 3 about here] Again, I would like to stress that the econometric specifications adjust the sample composition to the various personal, educational, and job-related characteristics of the respondents. Recall that the health status of the respondents is observed and controlled for. Likewise, adjustments are made for time effects, persistent differences between states, and the annual state unemployment rate.
The key identifying assumption, the common time trend assumption, is likely to hold. It assumes the absence of unobservables that generate different outcome dynamics for the treatment and control group. It is worth mentioning that a selection on observables story is very plausible in the present setting. In the first place, it is the MHI/PHI insurance status that determines treatment (see Table 1 ). Almost all factors that determine whether respondents are insured under the MHI or PHI-such as occupational status and income-are observed.
A method to check the absence of distorting unobservable effects is to estimate placebo regressions for years without a reform. I make use of this method in the next section. Figure 1 shows the evolution of the outcome variable for Treatment Group 1, 2 and the Control Group over time. 10 Even without the correction for observables, we observe parallel evolution in the three groups during the pre-reform years. After the reform, the incidence of convalescent care programs in the control group remained fairly stable, whereas we observe a clear, distinct, and parallel decrease for the treatment groups.
[Insert Figure 1 The drawbacks and limitations of DiD estimation are extensively debated. A particular concern is the underestimation of OLS standard errors due to serial correlation in the case of long time horizons as well as unobserved (treatment and control) group effects (Bertrand et al., 2004; Donald and Lang, 2007; Angrist and Pischke, 2009 ). To address the serial correlation issue, we focus on short time horizons. In addition, to provide evidence on whether unobserved common group errors might be a serious threat to our estimates, in robustness checks, we cluster on the state×year (16×5 = 80 clusters) level (Angrist and Pischke, 2009) .
A crucial issue in most studies trying to evaluate policy reforms is, besides the absence of a control group, selection into or out of the policy intervention. Selection issues are addressed since I am in the unusual position of having a framework in which two almost totally independent health care systems exist side by side, as explained in Section 2. On the one hand, this provides a well-defined control group. On the other hand, I do not need to fear that reform-induced selection has distorted the results, as there is virtually no switching between the MHI and the PHI, and since all MHI-insured persons are covered by universal health plans. Due to strict German regulations, a switch to the PHI was only legally allowed for a small fraction of optionally MHI-insured individuals, and I am able to identify and exclude these cases when running robustness checks. In my dataset, only 1.6 percent of those who were insured under the MHI for at least one year switched to the PHI between 1994 and 1998. The rate did not increase after the reform. Only 1.3 percent of those who were insured under the MHI in 1995 switched to the PHI in 1997 or 1998.
We need to consider the possibility of pull-forward effects. Convalescent care programs are usually planned several months or even years in advance. Since the first policy reform plans were made public at the end of 1995 (Handelsblatt, 1995) , it may be that a significant portion of the MHI-insured received their convalescent care therapy in 1996 instead of 1997. In the empirical application, I check for anticipation effects.
Admittedly, it may have been that, due to rising awareness and increased political pressure, the MHI funds were more restrictive in their authorization of therapy programs during the period when the reforms were under political discussion, i.e., in 1996. As for anticipation effects that might have been triggered by the insured, one can test for such effects by either excluding the year 1996 from the analysis or by adding an interaction term between 1996 and the treatment indicator to the analysis.
To be able to fully attribute changes in the incidence to changes in the demand for convalescent care programs, supply-side effects should not play a role. I found no indications of supply-side constraints. In contrast, there are reports about the deepest crisis in the market for convalescent care since the end of the Second World War (Handelsblatt, 1998) . Dozens of medical facilities and health spas closed and, hence, there is strong evidence of excessive supply. This is also supported by official statistics stating that the utilized bed capacity of all facilities strongly decreased, from 83.2 percent in 1996 to 62.3 percent in 1997 (German Federal Statistical Office, 2010).
Individuals insured under the MHI who were for some reason exempted from copayments are not identifiable. For example, people whose annual copayments for pharmaceuticals, health care services, or medical devices exceeded a certain percentage of their disposable household income could have applied for a case of hardship. 11 However, at that time, the German Spa Association claimed that the public was widely unaware of the exemption clauses. Therefore this should not downwardly bias the results severely.
As mentioned in Section 2.2, the third reform allowed employers to deduct two days of paid vacation for every five days that an employee was absent from work due to convalescent care 11 The usual threshold is 2 percent of disposable household income; for people with chronic diseases it is 1 percent.
therapy. The fourth reform cut statutory (short-term) sick pay. In contrast to the other reforms, these two reforms are rather indirect cost containment measures since they decreased the statutory minimum standards. Since employers are always free to provide fringe benefits on top of statutory requirements, reforms three and four simply increased employers' capacity to act.
I cannot observe which employers enforced these reforms strictly and passed on the decrease in social law minimum standards one-to-one to their employees. Anecdotal evidence and polls suggest that this might have been the case for about 50 percent of all potentially treated, i.e., private-sector employees (Ridinger, 1997; Jahn, 1998) . Using all private-sector employees jointly as treatment group, Ziebarth and Karlsson (2010) show that the cut in statutory short-term sick pay significantly reduced absenteeism. Since I apply the same approach in this setting, I
should be able to identify potential reform effects. Indeed, one of the main objectives of this paper is precisely to evaluate the effectiveness of direct cost containment measures such as copayment increases, which apply to the entire population, as compared to indirect measures such as decreasing legal minimum requirements, which only increase employers' options to regulate work conditions at the firm level.
As a last point, it should be kept in mind that the identification strategy for the differencein-differences regression models is based on various specifications. In total, I estimate three distinct models, each of which compares different mutually exclusive and differently affected subsamples. In addition, I run various robustness checks, which enables me to automatically cross-check the consistency and plausibility of the reform effects identified.
Results
Assessing the reforms' effectiveness Table 4 shows the results for Model 1, 2, and 3. For each model, I display the "raw" differencein-differences (DiD) estimate as well as the estimates obtained from a Probit and an OLS specification with the full set of covariates. The raw estimate represents what we see in Figure   1 , which displays the unconditional trends for the various subsamples over time. All models in Table 4 use an unbalanced panel, and each column represents one DiD model. DiD always stands for the DiD estimate.
Model 1 makes use of the treatment indicator T1 and compares the pre-post-reform outcome difference for Treatment Group 1 to the pre-post-reform outcome difference for the Control Group. Since Treatment Group 1 was affected by all four cost containment measures and the Control Group by none, Model 1 estimates the net effect of all reforms on the incidence of convalescent care programs. Column (1) gives the raw estimate, column (2) the Probit estimate, and column (3) the OLS estimate under the inclusion of all covariates.
All three estimates for Model 1 yield significantly negative reform effects on the incidence of convalescent care programs. Moreover, all three estimates are fairly robust and lie within the same confidence intervals. The Probit and the OLS estimates in columns (2) and (3) are especially close to one another, which suggest that functional form assumptions do not seem to matter here. The pre-reform incidence of convalescent care programs for Treatment Group 1 is 0.0355, i.e., 3.55 percent. Relating the percentage point estimate (-0.0081) from my preferred specification in column (2) to this pre-reform incidence rate suggests that all reforms jointly decreased the demand for convalescent care programs by 22.8 percent.
[Insert Table 4 about here]
Model 2 disentangles the effects of reforms one and two from the effects of reforms three and four.
Reform 1 doubled the daily copayments for convalescent care treatments. Reform 2 reduced the legally codified standard length of the therapy and increased the waiting times between two therapies. Reform 3 cut statutory sick leave, while Reform 4 cut paid vacation in case of work absences due to convalescent care treatments. Model 2 contrasts those who were affected by reforms one and two (Treatment Group 2) with those who were completely unaffected by all health reforms (Control Group). It employs the treatment indicator T2.
Again, all three estimates are similar in magnitude: all are negative and significantly different from zero, they are insensitive to the inclusion of covariates, and the results from the OLS and Probit models barely differ. All DiD point estimates fall within the same confidence intervals than the ones in Model 1. The average pre-reform convalescent care incidence for Treatment Group 2 was 0.0502, and hence the -0.0136 percentage point estimate of the Probit model in column (5) translates into a reform-induced decrease of about -27.1 percent. This suggests that reforms one and two are responsible for the decrease in demand for convalescent care programs.
In the robustness checks below, I provide evidence that the copayment doubling is probably responsible for the bulk of this decrease. My findings below suggest that the increase in waiting times did not contribute much to the decrease and that the legally codified reduction in the standard length of treatments merely reduced the average duration of treatments.
Model 3 compares those affected by all four reforms (Treatment Group 1) to those affected by reforms one and two (Treatment Group 2). I thereby assess the effects of reforms three and four jointly, i.e., the cuts in paid leave. The results of Model 3 strongly confirm the findings of Model 1 and Model 2: columns (7) to (9) Although entitled to take paid leave in addition to their paid vacation, many employees fear negative job consequences, especially when unemployment rates are high. Second, the cut in sick pay did not necessarily impose any limitation on the insured since their decision may have been between either going to a convalescent care facility or simply staying home to recover. In any case, the patient would have been on sick leave. If necessary, physicians usually recommend treatments in spa towns, but if patients prefer to stay home on sick leave, their wishes are usually respected.
The entire setup and the fact that all results are based on a comparison of three mutually exclusive subsamples gives rise to another means of calculating the effects for Model 2 and the first two reforms: one can simply subtract the estimates from Model 3 from those from Model 1, i.e., subtract the effects of reforms three and four from the net effect of all reforms. It is easy to see that this exercise yields very consistent alternative estimates for Model 2 that are almost identical to the direct estimates in columns (5) and (6) The first column of Panel A is the same estimate as the one in column (5) of Table 4 (-0.0136). This is the "standard" estimate. Column (2) excludes 1996 from the specification. Since the copayment doubling was first announced in December 1995, is it likely that pre-reform 1996 is 12 Here I focus on Model 2 since it includes more observations than Model 1 and therefore yields a more precise estimation. Moreover, as such, I am able to run checks on the effectiveness of Reform 2. The results for Model 1 are very similar and available upon request from the author.
Robustness checks
contaminated by either pull-forward effects triggered by the insured or by supply-side effects triggered by MHI sickness funds or the SPI. The MHI and SPI might have been more restrictive in the authorization of treatments due to rising public awareness and political pressure. Indeed I evidence of this. Omitting 1996, the DiD estimate shrinks slightly and translates into a decrease of about 21 percent in demand. Column (3) also supports this result, since the short-run reform effect obtained by comparing 1996 to 1997 is larger than the standard estimate in column (1) and -0.018. 13
Reform 2 increased the waiting period between treatments for MHI-insured from three to four years. The last column in Panel A tests whether the increase in waiting times reduced the incidence of convalescent care programs in the short run. The extension of the waiting period did not apply to individuals needing urgent medical treatment. As detailed in Section 2, people insured under the MHI have free choice of doctors, and there are almost no waiting times for doctor appointments in Germany. Thus, it is unlikely that the increase in waiting times had a substantial effect, since finding a doctor to write a prescription for treatment is not usually difficult. The increase in the waiting period forced patients who received treatment in 1994 (1995) to wait until 1998 (1999) instead of 1997 (1998) in the absence of urgent medical reasons.
Thus, if the increased waiting period had a substantial impact, I would measure a stronger reform effect for 1997 than for 1998. Column (5) of Table 5 shows that the reform effect in 1998 was not stronger than in 1997. I take this as evidence that the increased waiting period had no significant (short-term) effect on the demand for convalescent care.
The second element of Reform 2 was the reduction of the standard length of convalescent care from four to three weeks. The standard length is codified in the Social Code Book and applies universally to everyone who is insured under MHI. Exceeding the standard length is only possible in case of urgent medical reasons. The decision to deviate from the legally codified standard length can only be made by the attending physician after consulting the sickness fund to authorize the prolongation. Since the SOEP does not include information on the length of therapy, I cannot estimate the effect of the reduction in the standard length using a regression model. However, official data is available on the average treatment length and the total number of days spent in inpatient medical facilities for convalescent care treatments. These official data represent average values for the whole of Germany. According to these data, the average treatment length for all insured individuals decreased by almost 4 days from 31.0 (30.2) days in 1995 (1996) to 27.3 (26.4) days in 1997 (1998) (German Federal Statistical Office, 2010) . The 13 Please note that this is not true in a strict statistical sense since the confidence intervals overlap.
figures provide evidence that reducing the legally codified standard length was an effective tool to reduce the real length of treatments. On the other hand, it is unlikely that reducing the legal standard length of therapies had a substantial impact on the incidence of convalescent care therapy, i.e., on the decision to go to a health spa. However, there is no way to empirically prove this assumption.
[Insert Table 5 I exclude health variables in column (4) since the health status might be endogenous if measured after a convalescent care therapy. 14 The resulting estimate is very robust.
The last column in Panel B clusters standard errors on a higher aggregated level to test whether the common group error structure might be a serious issue in this setting (Angrist and Pischke, 2009 ). As can be seen, there is no evidence of this.
[Insert Table 6 about here]
In Table 6 , I display placebo regressions for Model 1, 2, and 3 and Probit as well as OLS specifications. Placebo regressions are a common means to test the common time trend assumption. Finding significant reform effects for years without a reform would cast serious doubts on the plausibility of the common time trend assumption. I use 1994 and 1995 as pseudo-reform years 14 Keep in mind that health status refers to the time of the interview, whereas the information about convalescent care programs is sampled retrospectively for the previous calendar year. As explained at the beginning of Section 3, if a respondent was interviewed in two subsequent years, I match the current health status information in year t0 with the convalescent care information from year t1 which refers to year t0. Since two-thirds of all interviews were carried out between January and March, the health status is likely to have been measured before the medical treatment.
and, apart from that, the same setup as above. All twelve placebo regression estimates are close to, and not significantly different from, zero.
Reduction in health expenditures
Since reducing health expenditures was the main intention behind the policy reforms, I perform a rough calculation of the decrease in public health expenditures using official data. Official data is available on the total sum that was spent on convalescent care by the public social insurance. Taking the simple difference in expenditures in 1997/1998 vs. 1994/1995 yields a total savings estimate of e 835 million per year. This represents a decrease in spending of 12.5 percent (German Federal Statistical Office, 2010) . It should be kept in mind, however, that time trends are included in this savings estimate.
As copayments were doubled, this reform raised additional revenues. However, official data show that the total number of convalescent care days consumed decreased by 22 percent from 57 million in 1994 /1995 to 44.5 million in 1997 (German Federal Statistical Office, 2010 .
Multiplying each sum by the pre-and post-reform copayments and taking the difference suggests that increasing copayments not only effectively dampened the demand for convalescent care but it also raised additional revenues of about e 435 million per year. 15
Discussion and Conclusion
In this article, I empirically assess the effectiveness of different cost containment measures within a unifying framework. In Germany, from 1997 on, four different health reforms were implemented in order to dampen the demand for convalescent care therapies, to fight moral hazard, and to decrease public health expenditures. At that time, experts claimed that around a quarter of all convalescent care therapies were unnecessary (Schmitz, 1996; Sauga, 1996) . In 1995, the German public social insurance system spent e 7.6 billion for 1.9 million convalescent care treatments.
Given the price elasticity of demand, convalescent care treatments can be considered good proxies for health care demand in general (Wedig, 1988; Ziebarth, 2010) .
Two of the health care cost containment measures evaluated applied solely, but universally, to those insured with public health insurance. In Germany, public health insurance coexists with private health insurance providers and strict legal regulations prevent switching between the two independent systems. Privately insured people were not affected by the two reforms and concerns about treatment selection are addressed. Moreover, since the other two of the four cost containment measures only applied to employees in the private sector, I am able to define various subsamples that were affected differently by the reforms. Hence, my empirical findings are based on various difference-in-differences models that compare different mutually exclusive subsamples.
The consistency of the findings across the models, combined with the robustness checks, allows me to conclude the following: first, all reforms, combined, decreased the demand for convalescent care therapies by about 20 percent. Second, doubling the daily copayments for convalescent care treatments was by far the most effective cost containment measure. This measure was responsible for the major part of the total decline in demand.
Third, descriptive evidence from official data suggests that a legally codified reduction in the standard length of the therapies was effective in reducing the true length of the therapies.
Fourth, I find no evidence that increasing the waiting times between two treatments had any significant effect on the decision to go for convalescent care.
Fifth, while all these policy measures applied universally to every publicly insured person, two other measures evaluated here applied in a rather indirect way. They reduced statutory minimum standards and increased the employers' options to set firm-specific employment conditions. The first of these indirect measures allowed employers to deduct two days of paid vacation for every five days that an employee was unable to work due to a convalescent care therapy. The second cut statutory sick pay for which employees are eligible during convalescent care treatments. I do not find any evidence that these soft cost containment measures were effective in reducing the demand for convalescent care programs. These findings let me conclude that, sixth, indirect measures that reduce statutory minimum conditions in the labor market are far less effective in achieving a specific predetermined policy goal; direct measures that apply universally are much more effective.
As a last exercise, using administrative data, I roughly calculate the reduction in public health expenditures that was induced by all reforms. My back-of-the-envelope calculations suggest that public health expenditures decreased by about e 800 million (-12.5 percent) per year due to the decline in the demand for convalescent care. Moreover, doubling the daily copayments raised additional revenues of about e 400 million per year.
The question to what degree such policy reforms succeed in reducing moral hazard or whether they actually lead to adverse health outcomes is difficult to quantify and is beyond the scope of this paper. The overall decrease in demand fits well with the a priori claims by health experts that a quarter of all pre-reform therapies were unnecessary. Although it is unlikely that moral hazard was completely eliminated by the reforms, it is probable that the majority of the decrease is due to a reduction in moral hazard and led to greater efficiency in the convalescent care market.
On the other hand, if medically necessary therapies were not provided, this may have led to adverse health outcomes and, in the long run, to even higher overall health expenditures.
Especially in the case of convalescent care, it is difficult to balance the prevailing degree of moral hazard against potential long-term health improvements that may reduce health expenditures and exert positive external effects. Some studies find positive health effects of health spa stays: patients with chronic diseases experienced reductions in pain and blood pressure, and for a sample of employees, beneficial effects on physical and particularly mental health, such as improved sleep quality, were found (Sekine et al., 2006; Cimbiz et al., 2005; Constant et al., 1998) . While two of these studies are purely correlation-based, Constant et al. (1998) estimate the short-term effects of a randomized trial on 224 patients with chronic lower back pain. However, I am unaware of studies evaluating the long-term health effects of convalescent care therapies. Assessing the long-term effects of health care on health outcomes as well as on health expenditures is a promising field for future research. In contrast to Appendix A, this table gives mean values separately for the treatment and control groups. As detailed in Section 3, convalescent care is the overall incidence of convalescent care programs. * p<0.1, ** p<0.05, *** p<0.01; in columns (1), (3), and (5), marginal effects are displayed; they are calculated at the means of the covariates except for T1 (T2, T3)(=1) and DiD94 (DiD95)(=1). All columns but (2), (4), and (6) estimate OLS models. The dependent variable is convalescent care and measures the incidence of convalescent care programs (see Section 3). Every cell represents one regression model. Columns (1) and (2) use T1, columns (3) and (4) use T2, and columns (4) and (5) use T3 (see Section 3 for further details). Each model in columns (1) and (2) has 27,791 observations; each model in columns (3) and (4) has 42,019 observations and columns (5) and (6) are based upon 61,288 observations. All models compare the same groups of (pseudo) treated and (pseudo) non-treated respondents than the non-placebo models. DiD94 (DiD95) is an interaction term between the treatment indicator (T1, T2, or T3) and the year 1994 (1995). Standard errors in parentheses are adjusted for clustering on person identifiers.
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